Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML

This study evaluates the efficacy and safety of the combination of idarubicin and cytarabine induction followed by intermediate-dose cytarabine consolidation with venetoclax in the treatment of newly diagnosed adult acute myeloid leukemia (AML). This study includes the induction and consolidation phases of AML treatment.

Trial Details

NCT ID
NCT06232694
Phase
NA
Sponsor
The First Affiliated Hospital with Nanjing Medical University
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;
  • Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;
  • utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Newly diagnosed primary AML patients. Diagnostic criteria refer to the 2022 WHO classification.
  • Age between 18 and 60 years old.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 (see Appendix 2).
  • Cardiac ultrasound LVEF ≥ 45%.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →